Summary Altered expression of the retinoblastoma (RB) tumour-suppressor gene product (pRB) 
The prognosis of patients with soft-tissue sarcomas has traditionally been determined by clinical and histopathological features of the tumour such as grade, size and depth. A number of staging systems have been developed which broadly categorise patients into groups of different survival potential (Russel et al., 1977; Beahrs et al., 1988; Shiu and Brennan, 1989) . To date there is no universally accepted system for the staging of soft-tissue sarcomas, although the most widely employed is the AJCC (Beahrs et al., 1988) . Recent advances in the recognition and understanding of molecular genetic events occurring in the pathogenesis of human sarcomas have resulted in attempts to define new prognostic markers.
Children affected with the hereditary form of retinoblastoma often develop a second malignancy several years after successful treatment of their primary tumour (Abramson et al., 1984) . Most of these secondary neoplasms are bone or soft-tissue sarcomas (Hansen et al., 1985) . In contrast, secondary neoplasms are uncommon in patients with the sporadic form of the disease. Knudson proposed that retinoblastoma developed as the result of two mutations inactivating both alleles of a single gene (Knudson, 1971) . The RB gene maps to chromosome 13, band 13q14, and it encodes for a 110 kDa nuclear phosphoprotein (Friend et al., 1986; Fung et al., 1987; Lee et al., 1987) . pRB is phosphorylated in a cell cycle-dependent manner; underphosphorylated pRB products are the predominant form in G,, exerting a growth-suppressive effect (Buchkovich et al., 1989;  DeCaprio et Xu et al., 1991) . Since pRB does not seem to possess sequence-specific DNA-binding activity, it is postulated that the negative regulatory effect of underphosphorylated pRB is through complex formation with DNAbinding proteins (DeFeo-Jones et al., 1991) , such as the transcription factor E2F (Chepallan et al., 1991) . In addition, pRB appears to be involved in the differentiation programme of certain cell lineages, since homozygous mutant RB mouse embryos die during embryonic development with major derangements of the central nervous system and erythropoiesis (Jacks et al., 1992; Lee et al., 1992) . In recent years numerous lines of evidence have confirmed the concept that the RB gene is the prototypical tumour-suppressor gene (Huang et al., 1988; Sumegi et al., 1990) . RB mutations and altered patterns of pRB expression have been detected in other malignancies, including soft-tissue sarcomas (Cance et al., 1990; Stratton et al., 1990; Wunder et al., 1991) , acute myelogenous leukaemia (Kornblau et al., 1992) , breast cancer Varley et al., 1989) , bladder carcinomas (Cairns et al., 1991; Cordon-Cardo et al., 1992; Logothetis et al., 1992) and small-cell carcinoma of the lung (Harour et al., 1988; Hensel et al., 1990) .
We previously studied a group of 44 primary high-grade bone and soft-tissue sarcomas of all age groups using immunohistochemistry, and observed a 70% incidence of altered pRB expression (Cance et al., 1990) . Patients whose tumours had strong homogeneous expression of pRB had significantly better survival than patients with heterogeneous or absent expression of the pRB gene product. Given the potential clinical significance of these findings, we have extended our original study and analysed a larger cohort of 174 adult soft-tissue sarcomas for pRB expression. In the present analysis, all bone and paediatric tumours were excluded; however, specimens from metastatic sarcomas were included but were analysed separately. The avidin-biotin complex immunoperoxidase technique was the method used for the present study. Briefly, frozen tissue blocks were cut to 6 1tm thin sections placed on microslides and formalin fixed. The Rb-PMG3-245 antibody (final concentration, 10 g ml-') and the non-specific negative control antibody (used at the same concentration) were applied to consecutive sections of the same tumour. After extensive washing, tissues were incubated with biotinylated horse antimouse secondary antibodies (Vector Laboratories, Burlingame, CA, USA) for 30 min at a concentration of 1:100, followed by avidin-biotin-peroxidase complexes (Vector Laboratories) at 1:25 dilution. Diaminobenzidine was used as the final chromogen and ethyl green as the nuclear counterstain.
Statistical methods
Fisher's exact test was used to assess the association between clinicopathological factors and altered patterns of pRB (Mehta and Patel, 1983) . The Kaplan-Meier method (Kaplan RB Meier, 1958) was used to estimate the survival functions. All non-tumour-related deaths were censored in the Kaplan-Meier analysis. The log-rank test (Peto et al., 1977) was used to compare differences in survival between groups of patients.
Results
The histopathological and relevant clinical characteristics of this group of soft-tissue sarcomas are summarised in Table I (Hansen et al., 1985; Friend et al., 1986) . This early observation led to questions concerning the potential role of RB in the tumorigenesis of sporadic bone and soft-tissue sarcomas. Subsequent studies revealed that RB mutations also occur in sporadic sarcomas. Stratton et al. (1989) found homozygous RB deletions in only 3 of 63 sarcomas analysed, and loss of heterozygosity in 5 of 22 informative cases. Reissmann et al. (1989) also found RB deletions in three of nine osteosarcomas and 4 of 29 soft-tissue sarcomas. These studies were conducted utilising restriction fragment length polymorphism and Southern blot assays in order to identify RB gene mutations. Subtle alterations, sufficient to decrease or abort RB gene expression, are usually undetectable when using these techniques and may explain the lower frequency of RB alterations reported.
Methods which are guided to the analysis of gene expression are known to be more sensitive in detecting underlying RB alterations. Wunder et al. (1991) , using Northern blot analysis, demonstrated an association between tumour grade and altered RB transcripts. They found low to undetectable RB mRNA levels in 10 of 25 high-grade bone and soft-tissue sarcomas analysed. In contrast, only 1 of 11 low-grade sarcomas and none of the four lipomas studied showed altered RB transcripts.
In a preliminary study from our group and for the present report, expression of pRB was assessed by the Rb-PMG3-245 monoclonal antibody and immunohistochemistry. This technique allows correlation of expression with microanatomic features and can identify the degree of heterogeneity and range of intensity of expression within a tumour. In our earlier series of 56 non-selected soft-tissue sarcomas, we showed that pRB was undetectable or heterogeneously expressed in 70% of the primary high-grade sarcomas, as well as in all metastatic lesions analysed (Cance et al., 1990 could reflect pRB variations that occur during cell cycle, either intercellular differences in the level of bound vs unbound pRB or its degree of phosphorylation. However, this last issue is unlikely since the antibody used (Rb-PMG3-245) detects both hypo-and hyperphosphorylated pRB products. In addition, while pRB expression in normal cells has been felt to be ubiquitous, recent analyses in normal tissue have documented low to undetectable pRB levels in association with specific cell types, including fibroblasts (Szekely et al., 1992; Cordon-Cardo and Richon, 1994) . It is then reasonable to postulate that well differentiated soft-tissue sarcomas with a low proliferative index have low to undetectable pRB expression, below the threshold of immunohistochemistry. It is interesting to note that the number of low-grade tumours displaying a homogeneous pRB phenotype decreased with disease progression from 30% in primary sarcomas to 18% in local recurrences. This change was paralleled with a concurrent increase in the percentage of pRB heterogeneous lesions. This inverse relationship between tumour progession and pRB expression was not demonstrated in the high-grade tumours. In those cases, the extent of heterogeneous and undetectable pRB levels was similar in primary and metastatic lesions.
In our original study we analysed the survival of 44 patients with primary high-grade bone and soft-tissue sarcomas from all age groups. We found that survival of patients with altered pRB levels was significantly shorter at 24 months than patients whose tumours had homogeneous pRB staining. In the present study we observed similar differences at 18 and 24 months of follow-up between survial and pRB-positive vs pRB-negative cases, as in our initial study. However, beyond 24 months pRB expression did not appear to influence the survival of adult patients with primary high-grade soft-tissue sarcomas. Given the current survival results, we updated the follow-up of our previous data and reanalysed the results to test the durability of our early differences (Figure 2) . At approximately 24 months the three curves begin to come together and the differences were no longer observed. It is not an unknown biological observation to see early differences lose their significance over time. For example, the contribution of various clinicopathological features of patients with sarcoma can vary according to duration of follow-up. Tumour grade is the dominant factor in early metastases, whereas the influence of this variable on the development of late metastases is equivalent (Gaynor et al., 1993) . The early survival advantage of the patients with pRB positive sarcomas may reflect a delay in metastatic potential which diminishes with time. Other important differences between the two studies are the exclusion of osteosarcomas and paediatric sarcomas, as well as the more than doubling of the sample size. Bone and paediatric sarcomas are known to have high response rates to chemotherapy. Consequently, the prognosis of these patients has been dramatically improved by the addition of adjuvant chemotherapy (Link et al., 1991) . This is not the case in adults with extremity soft-tissue sarcomas (Mazanet and Antman, 1991) . As for the number of patients studied, the potential for 'type II' statistical error is now reduced compared with our original study, in which conclusions were, in essence, based on the survival of 13 patients. In summary, based on data from this study we cannot ascribe prognostic significance to alterations in RB gene expression in adult soft-tissue sarcomas. Given the high percentage of abnormal RB gene expression in primary low-and high-grade sarcomas, it appears that alterations in the expression of this gene occur both frequently and early in the pathogenesis of soft-tissue sarcomas. Our data suggest that, in adult soft-tissue sarcomas, alterations of the RB gene may be more important in tumorigenesis or early tumour progression than in late disease stages. More studies are required comparing RB and other tumour-suppressor gene abnormalities developing in well-characterised groups of patients affected with soft-tissue sarcomas in order to evaluate their critical role as tumour markers able to stratify patients in prognostic categories.
